We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Fructosamine Levels Help Assess Pre-Op Glycemic Control

By HospiMedica International staff writers
Posted on 28 Nov 2017
Serum fructosamine could serve as an alternative to hemoglobin A1C (HbA1C) as a predictor of adverse surgical outcome in patients with diabetes or hyperglycemia, according to a new study.

Researchers at Thomas Jefferson University (TJU; Philadelphia, PA, USA) and Tel Aviv University (Israel) conducted a study that screened 829 patients undergoing primary total joint arthroplasty using serum HbA1c, fructosamine, and blood glucose levels. More...
All patients were followed, and total joint arthroplasty complications were evaluated, in particular surgical-site infection (SSI). Based on recommendations of the American Diabetes Association, an HbA1c level of 7% was chosen as indicative of poor glycemic control, which correlated with a fructosamine level of 292 μmol/L.

The results of the study revealed that high HbA1c levels did not predict increased risk of complications; high fructosamine levels, on the other hand, were associated with a greater risk for deep SSI infection, readmission, and reoperation. In addition, 35% of patients with fructosamine levels higher than the cut-off level of 292 μmol/L had no history of diabetes, indicating an increased risk in patients who might not otherwise have been identified. The study was published on November 15, 2017, in The Journal of Bone & Joint Surgery.

“This study gives us a better method for identifying patients who need intervention prior to surgery. It could be immensely useful in preventing life-threatening post-surgery complications,” said senior author Professor Javad Parvizi, MD, of TJU. “Because of its promising role in determining poorly controlled glucose levels, we have already begun to use the fructosamine test at our institution to determine who is at high risk of complications, and allocate resources to optimizing the glycemic control in these patients.”

“The fact that we can use this test to detect poor glucose control in non-diabetic patients may be significant, and could help us improve outcomes for non-diabetic patients as well,” said lead author Noam Shohat, MD, of TAU. “Clinical and preclinical studies have shown that even short-term spikes in blood sugar can impair the immune system, specifically innate immunity, and the body's ability to fight infection.”

Fructosamines result from glycation reactions between a sugar--fructose or glucose--and a primary amine, followed by isomerization. In a similar way to HbA1c, fructosamine tests determines the fraction of total serum proteins that have undergone glycation; since albumin is the most abundant protein in blood, fructosamine levels typically reflect albumin glycation. As albumin has a half-life of approximately 20 days, plasma fructosamine concentration reflects relatively recent (one to two week) changes in blood glucose, in comparison to HbA1c, which is an average of three months of change.

Related Links:
Thomas Jefferson University
Tel Aviv University


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: A UTSW clinical trial studied a treatment strategy for kidney cancer with inferior vena cava tumor thrombus (IVC-TT) that used targeted radiation on the tumor thrombus followed by surgery to remove the kidney. (Photo courtesy of UT Southwestern)

Targeted Radiotherapy Before Surgery Improves Control of Kidney Cancer Thrombus

Inferior vena cava tumor thrombus occurs when kidney cancer extends into the body’s largest vein, potentially obstructing blood flow, progressing toward the heart, and making surgery more complex.... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Brain PET imaging could help identify Alzheimer’s patients most likely to benefit from available therapies (Image Credit: iStock)

Amyloid and Tau PET Guide Selection and Monitoring of Alzheimer’s Therapy

Alzheimer’s disease is the most common form of dementia and can be difficult to distinguish from other causes of cognitive decline. According to the World Health Organization (WHO), 57 million people were... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.